Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer
10.3971/j.issn.1000-8578.2022.21.1466
- VernacularTitle:抗体偶联药物在晚期非小细胞肺癌中的研究进展
- Author:
Yarui CHEN
1
;
Jiangtao WANG
;
Quanlin GUAN
;
Wei JI
;
Fuzhi JIAO
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Non-small cell lung cancer;
Antibody-drug conjugates;
Targeted therapy
- From:
Cancer Research on Prevention and Treatment
2022;49(8):855-860
- CountryChina
- Language:Chinese
-
Abstract:
Although targeted, immune and other therapeutic strategies have become the first-line standard therapy for patients with advanced lung cancer, acquired drug resistance is still inevitable in most cases. The advent of antibody-drug conjugates (ADC) provides a new choice. ADC is a new anticancer drug formed by the coupling of targeted anti-tumor monoclonal antibodies and cytotoxic drugs. Compared with chemotherapeutic drugs, ADC has the advantages of high tolerance, accurate target recognition and little effect on non-cancer cells, and has shown good clinical benefits in the treatment of a variety of malignant tumors. This article reviews the application of ADC in advanced non-small cell lung cancer.
